美常安联合美沙拉嗪对溃疡性结肠炎患者炎症因子的影响  

The effect of Medilac-s capsule combined with mesalazine on inflammatory factors in patients with ulcerative colitis

作　　者：靳淑黎[1] 李自显[1] 李丽平[1] 

机构地区：[1]安阳地区医院消化科,河南濮阳455000

出　　处：《河南医学研究》2014年第12期16-18,共3页Henan Medical Research

基　　金：濮阳市科技攻关项目(010452)

摘　　要：目的:观察美常安联合美沙拉嗪治疗溃疡性结肠炎(ulcerative colitis,UC)患者的疗效及对血清炎症因子的影响。方法:将226例活动期UC患者随机分为观察组114例和对照组112例,对照组给予美沙拉嗪治疗,观察组在此基础上给予美常安治疗,对比两组疗效及白介素-8(IL-8)、白介素-10(IL-10)、肿瘤坏死因子α(TNF-α)及巨噬细胞抑制因子(MIF)等血清炎症因子的变化。结果:观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前观察组IL-8、TNF-α、MIF、IL-10含量与对照组差异无统计学意义(P>0.05),治疗后IL-8和TNF-α与对照组比较降低,差异有统计学意义(P<0.05),而MIF含量与对照组比较差异无统计学意义(P>0.05);血清中IL-10的含量在治疗后则有明显升高,且治疗组升高较对照组明显(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论:美常安联合美沙拉嗪治疗UC可明显提高治疗有效率,两者具有药物协同作用,能更好地控制病情,有较大的临床应用价值。Objective： To evaluate the curative effect of Medilac-s capsule combined with mesalazine and the influence on inflammatory factors in patients with ulcerative colitis. Methods： Two hundred and twenty six cases with active ulcerative colitis were randomly divided into the observation group（ n = 114） and the control group（ n = 112）. The observation group were treated with Medilac-s capsule combined with mesalazine while the control group were only treated with mesalazine. The curative effects in the two groups were compared. And the changes of IL-8,TNF-α,MIF and IL-10 in serum from patients with ulcerative colitis in the two groups were also compared.Results： The total efficiency in the observation group was higher than the control group and the difference was statistically significant（ P〈0. 05）. The concentrations of IL-8,TNF-α,MIF and IL-10 in the two groups were not significantly different before treatment（ P〈0. 05）. The concentrations of IL-8 and TNF-α were more lower in the observation group than the control group（ P〈0. 05）,while IL-10 was reverse after treatment（ P〈0. 05）. MIF was lower in the observation group than control group,but there was no statistics significance（ P〉0. 05）. The adverse reactions in the two group were similar（ P〉0. 05）. Conclusion： Medilac-s capsule combined with mesalazine could improve the effective rate in patients with active ulcerative colitis. The two drugs had synergistic effect and could control pathogenetic condition of patients with active ulcerative colitis. The two drugs have biggish clinical application values and good application prospect.

关 键 词：溃疡性结肠炎 美沙拉嗪 美常安 炎症因子 

分 类 号：R574.1[医药卫生—消化系统]